A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
A phase 1/2 trial of Rituximab, Glofitamab, Obinutuzumab in hodgkin lymphoma and non-hodgkin lymphoma, run by Bristol-Myers Squibb, now recruiting.
Overview
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas is a phase 1/2 interventional study registered as NCT06090539 by Bristol-Myers Squibb, with 460 participants planned, started 2023-12-29 and due to reach its primary completion in 2027-10-28. Interventions recorded: BMS-986458, Rituximab, Glofitamab/Obinutuzumab, Mosunetuzumab, Epcoritamab. Conditions listed: Relapsed/Refractory Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory No
Shares Golcadomide, Obinutuzumab, Rituximab, Non-Hodgkin lymphoma (all types).
- TrialA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Matu
Shares Glofitamab, Obinutuzumab, Rituximab, Non-Hodgkin lymphoma (all types).
- TrialA Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Shares Mosunetuzumab, Glofitamab, Obinutuzumab, Non-Hodgkin lymphoma (all types).
- TrialA Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
Shares Golcadomide, Rituximab, Non-Hodgkin lymphoma (all types), Bristol Myers Squibb.
- TrialA Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
Shares Mosunetuzumab, Rituximab, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.
- TrialA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Shares Glofitamab, Obinutuzumab, Rituximab, Non-Hodgkin lymphoma (all types).
- TrialA Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat
Shares Glofitamab, Obinutuzumab, Non-Hodgkin lymphoma (all types).
- TrialA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Th
Shares Epcoritamab, Rituximab, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.